Iovance Biotherapeutics, Inc.
IOVA · Healthcare
$8.28
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics announced that senior leadership will present at the Wells Fargo Healthcare Conference (September 10) and H.C. Wainwright Global Investment Conference (September 15). The company reported record Q2 2026 revenue of approximately $99M, with U.S. Amtagvi revenue reaching ~$91M and 66% year-over-year growth. Gross margin improved to 56%, and the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight
DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Iovance Biotherapeutics reported strong Q2 earnings with revenue of $99.3 million (up 66% year-over-year), driven primarily by its FDA-approved cancer treatment Amtagvi. The company also significantly reduced losses to $47.3 million from $111.7 million in the prior year. With blockbuster potential for Amtagvi and a path toward profitability, analysts believe the stock could rise further despite current valuation concerns.